Jolien M.R. Van der Meer

Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients

Janneke S. Hoogstad‐van Evert, Ralph J. A. Maas, Jolien M.R. Van der Meer et al. · Oncotarget · 2018 · 72 citations · Full text

Medicine, Immunology, Oncology +13

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Ralph J. A. Maas, Janneke S. Hoogstad‐van Evert, Jolien M.R. Van der Meer et al. · OncoImmunology · 2020 · 69 citations · Full text

Life Sciences, Immunology, Oncology +17

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

Jolien M.R. Van der Meer, Ralph J. A. Maas, Karolin Guldevall et al. · Cancer Immunology Immunotherapy · 2020 · 46 citations · Full text

Life Sciences, Immunology, Oncology +16

CD34 ⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg ^null mice

Jolien M.R. Van der Meer, Paul K.J.D. de Jonge, Anniek B. van der Waart et al. · OncoImmunology · 2021 · 19 citations · Full text

Life Sciences, Immunology, Oncology +17

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

Paul K.J.D. de Jonge, P.M.M. van Hauten, L. D. Janssen et al. · Cancer Immunology Immunotherapy · 2023 · 17 citations · Full text

Life Sciences, Biotechnology, Immunology +17